Basic science in Parkinson's disease: Its impact on clinical practice

Journal of Neurology

Volumn 258, Issue SUPPL. 2, 2011, Pages

  Schulz, Jörg B ^a,b   Gerlach, Manfred ^c   Gille, Gabriele ^d   Kuhn, Wilfried ^e   Müngersdorf, Martina ^f   Riederer, Peter ^c   Südmeyer, Martin ^g   Ludolph, Albert ^h  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b JARA BRAIN   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e Leopoldina Krankenhaus   (Germany)

^f Neurologie am Hackeschen Markt   (Germany)

^g HEINRICH HEINE UNIVERSITY   (Germany)

^h UNIVERSITY OF ULM   (Germany)

Author keywords

Basic science; History; Parkinson's disease; Treatment

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA TOCOPHEROL; AMANTADINE; APOMORPHINE; BROMOCRIPTINE; BULBOCAPNINE; CREATINE; DEFEROXAMINE MESYLATE; DOPA; DOPAMINE; ENTACAPONE; IPRONIAZID; LEVODOPA; MEMANTINE; MINOCYCLINE; RASAGILINE; RESERPINE; SELEGILINE; TOLCAPONE; UBIDECARENONE;

BRAIN DEPTH STIMULATION; CELL TRANSPLANTATION; CLINICAL PRACTICE; CONFERENCE PAPER; DISEASE MODEL; DRUG MECHANISM; DRUG POTENTIATION; GENETICS; HUMAN; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBTHALAMIC NUCLEUS;

ANIMALS; ANTIPARKINSON AGENTS; DISEASE MODELS, ANIMAL; HUMANS; NEUROSCIENCES; PARKINSON DISEASE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 79959976519     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-011-6040-y     Document Type: Conference Paper

References (72)

1. Benabid AL, Pollak P, Louveau A, Henry S, de Rougemont J (1987) Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl Neurophysiol 50:344-346 (Pubitemid 18043161)
2. Benazzouz A, Gross C, Feger J, Boraud T, Bioulac B (1993) Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. Eur J Neurosci 5:382-389 (Pubitemid 23108592)
3. Bergman H, Wichmann T, DeLong MR (1990) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249:1436-1438
4. Bernheimer H, Birkmayer W, Hornykiewicz O (1962) Behavior of monoamine oxidase in the brain of man after therapy with monoamine oxidase inhibitors. Wien Klin Wochenschr 74:558-559
5. Birkmayer W, Hornykiewicz O (1961) The L-3, 4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien Klin Wochenschr 73:787-788
6. Birkmayer W, Riederer P, Youdim MB, Linauer W (1975) The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm 36:303-326
7. Bjorklund A, Stenevi U (1979) Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain Res 177:555-560 (Pubitemid 10241286)
8. Blaschko H, Richter D, Schlossmann H (1937) The oxidation of adrenaline and other amines. Biochem J 31:2187-2196
9. Bormann J (1989) Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur J Pharmacol 166:591-592 (Pubitemid 19195356)
10. Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211 (Pubitemid 36007810)
11. Calne DB, Teychenne PF, Leigh PN, Bamji AN, Greenacre JK (1974) Treatment of parkinsonism with bromocriptine. Lancet 2:1355-1356
12. Carlsson A, Lindquist M, Magnusson T (1957) 3, 4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180:1200
13. Carlsson A, Lindqvist M, Fila-Hromadko S, Corrodi H (1962) Synthese von Catechol-O-methyl-transferase-hemmenden Verbindungen. In den Catecholaminmetabolismus eingreifende Substanzen. 1, Mitteilung. Helvetica Chimica Acta 45:270-276
14. Carlsson A, Lindqvist M, Magnusson T, Waldeck B (1958) On the presence of 3-hydroxytyramine in brain. Science 127:471
15. Cho MS, Lee YE, Kim JY, Chung S, Cho YH, Kim DS, Kang SM, Lee H, Kim MH, Kim JH, Leem JW, Oh SK, Choi YM, Hwang DY, Chang JW, Kim DW (2008) Highly efficient and large-scale generation of functional dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci USA 105:3392-3397 (Pubitemid 351723563)
16. Chu Y, Kordower JH (2010) Lewy body pathology in fetal grafts. Ann NY Acad Sci 1184:55-67
17. Corrodi H, Fuxe K, Hokfelt T, Lidbrink P, Ungerstedt U (1973) Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons. J Pharm Pharmacol 25:409-412
18. Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, Kopin IJ (1979) Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1:249-254 (Pubitemid 10123385)
19. de Lau LML, Schipper CMA, Hofman A, Koudstaal PJ, Breteler MMB (2005) Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam study. Arch Neurol 62:1265-1269 (Pubitemid 41168354)
20. DeLong MR (1990) Primate models of movement disorders of basal ganglia origin. TINS 13:281-285 (Pubitemid 20193459)
21. Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schöfer H, Bötzel K, Daniels C, Deutschlönder A, Dillmann U, Eisner W, Gruber D, Hamel W, Herzog J, Hilker R, Klebe S, Kloss M, Koy J, Krause M, Kupsch A, Lorenz D, Lorenzl S, Mehdorn HM, Moringlane JR, Oertel W, Pinsker MO, Reichmann H, Reuss A, Schneider G-H, Schnitzler A, Steude U, Sturm V, Timmermann L, Tronnier V, Trottenberg T, Wojtecki L, Wolf E, Poewe W, Voges J, German Parkinson Study Group NS (2006) A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 355:896-908 (Pubitemid 44315982)
22. Dezawa M, Kanno H, Hoshino M, Cho H, Matsumoto N, Itokazu Y, Tajima N, Yamada H, Sawada H, Ishikawa H, Mimura T, Kitada M, Suzuki Y, Ide C (2004) Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation. J Clin Invest 113:1701-1710 (Pubitemid 39071662)
23. Dunnett SB, Bjorklund A, Stenevi U, Iversen SD (1981) Behavioural recovery following transplantation of substantia nigra in rats subjected to 6-OHDA lesions of the nigrostriatal pathway. I. Unilateral lesions. Brain Res 215:147-161 (Pubitemid 11123238)
24. Dunnett SB, Bjorklund A, Stenevi U, Iversen SD (1981) Behavioural recovery following transplantation of substantia nigra in rats subjected to 6-OHDA lesions of the nigrostriatal pathway. II. Bilateral lesions. Brain Res 229:457-470 (Pubitemid 12242552)
25. Ehringer H, Hornykiewicz O (1960) Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin Wochenschr 38:1236-1239
26. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, Dillon S, Winfield H, Culver S, Trojanowski JQ, Eidelberg D, Fahn S (2001) Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344:710-719 (Pubitemid 32204988)
27. Freed CR, Leehey MA, Zawada M, Bjugstad K, Thompson L, Breeze RE (2003) Do patients with Parkinson's disease benefit from embryonic dopamine cell transplantation? J Neurol 250(Suppl 3):III44-III46
28. Funk C (1911) Synthesis of DL-3:4-dihydroxyphenylalanine. J Chem Soc 99:554-557
29. Gerlach M, Riederer P, Przuntek H, Youdim MB (1991) MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol 208:273-286
30. Gispert-Sanchez S, Auburger G (2006) The role of protein aggregates in neuronal pathology: guilty, innocent, or just trying to help? J Neural Transm 70:111-117 (Pubitemid 44622187)
31. Hatcher JM, Pennell KD, Miller GW (2008) Parkinson's disease and pesticides: a toxicological perspective. Trends Pharmacol Sci 29:322-329
32. Hely MA, Morris JGL, Reid WGJ, Trafficante R (2005) Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 20:190-199 (Pubitemid 40361122)
33. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427-442
34. Holtz P, Credner K (1941) Decarboxylierung von dioxyphenylalanin (Dopa) und Histidin in vivo. Naturwissenschaften 29:649-650
35. Ilieva H, Polymenidou M, Cleveland DW (2009) Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol 187:761-772
36. Ishihara LS, Cheesbrough A, Brayne C, Schrag A (2007) Estimated life expectancy of Parkinson's patients compared with the UK population. J Neurol Neurosurg Psychiatry 78:1304-1309 (Pubitemid 350221407)
37. Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17:1285-1297
38. Karpinar DP, Balija MBG, Kügler S, Opazo F, Rezaei-Ghaleh N, Wender N, Kim H-Y, Taschenberger G, Falkenburger BH, Heise H, Kumar A, Riedel D, Fichtner L, Voigt A, Braus GH, Giller K, Becker S, Herzig A, Baldus M, Jöckle H, Eimer S, Schulz JB, Griesinger C, Zweckstetter M (2009) Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO J 28:3256-3268
39. Kim DW, Chung S, Hwang M, Ferree A, Tsai HC, Park JJ, Nam TS, Kang UJ, Isacson O, Kim KS (2006) Stromal cell-derived inducing activity, Nurr1, and signaling molecules synergistically induce dopaminergic neurons from mouse embryonic stem cells. Stem cells 24:557-567 (Pubitemid 44464759)
40. Knoll J (1983) Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol Scand 95:57-80 (Pubitemid 14162445)
41. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW (2008) Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 14:504-506 (Pubitemid 351655212)
42. Kordower JH, Chu Y, Hauser RA, Olanow CW, Freeman TB (2008) Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord 23:2303-2306
43. Kornhuber J, Bormann J, Retz W, Hubers M, Riederer P (1989) Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol 166:589-590 (Pubitemid 19195355)
44. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979-980 (Pubitemid 13189531)
45. Li J, Englund E, Holton J, Soulet D, Hagell P, Lees A, Lashley T, Quinn N, Rehncrona S, Björklund A, Widner H, Revesz T, Lindvall O, Brundin P (2008) Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 14:501-503 (Pubitemid 351655211)
46. Li JY, Englund E, Widner H, Rehncrona S, Bjorklund A, Lindvall O, Brundin P (2010) Characterization of Lewy body pathology in 12-and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Mov Disord 25:1091-1096
47. Limousin P, Pollak P, Benazzouz A, Hoffmann D, Le Bas JF, Broussolle E, Perret JE, Benabid AL (1995) Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 345:91-95
48. Lindvall O, Brundin P, Widner H, Rehncrona S, Gustavii B, Frackowiak R, Leenders KL, Sawle G, Rothwell JC, Marsden CD et al (1990) Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 247:574-577
49. Marras C, Lang A (2008) Changing concepts in Parkinson disease: moving beyond the decade of the brain. Neurology 70:1996-2003
50. Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, Shannon KM, Nauert GM, Perl DP, Godbold J, Freeman TB (2003) A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54:403-414 (Pubitemid 37072046)
51. Olanow CW, Gracies JM, Goetz CG, Stoessl AJ, Freeman T, Kordower JH, Godbold J, Obeso JA (2009) Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. Mov Disord 24:336-343
52. Ordenstein L (1867) Sur la paralysie agitante et la sclérose en plaque generalisée. Martinet, Paris
53. Parkinson J (1817) An essay on the shaking palsy. Sherwood, Neely, and Jones, London
54. Perlow MJ, Freed WJ, Hoffer BJ, Seiger A, Olson L, Wyatt RJ (1979) Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 204:643-647 (Pubitemid 9221523)
55. Perrier AL, Tabar V, Barberi T, Rubio ME, Bruses J, Topf N, Harrison NL, Studer L (2004) Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci USA 101:12543-12548 (Pubitemid 39122060)
56. Peschanski M, Defer G, N'Guyen JP, Ricolfi F, Monfort JC, Remy P, Geny C, Samson Y, Hantraye P, Jeny R et al (1994) Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain 117(Pt 3):487-499 (Pubitemid 24225897)
57. Roy NS, Cleren C, Singh SK, Yang L, Beal MF, Goldman SA (2006) Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomeraseimmortalized midbrain astrocytes. Nat Med 12:1259-1268 (Pubitemid 44706928)
58. Sano H (2000) Biochemistry of the extrapyramidal system Shinkei Kennkyu No Shinpo, Adv Neurol Sci (ISSN:0001-8724) 1960, 5:42-48;
59. Parkinsonism Relat Disord 6:3-6
60. Schulz J (2008) Update on the pathogenesis of Parkinson's disease. J Neurol 255(S5):3-7
61. Schulz J, Beal M (1994) Mitochondrial dysfunction in movement disorders. Curr Opin Neurol 7:333-339 (Pubitemid 24243738)
62. Schulz TC, Noggle SA, Palmarini GM, Weiler DA, Lyons IG, Pensa KA, Meedeniya AC, Davidson BP, Lambert NA, Condie BG (2004) Differentiation of human embryonic stem cells to dopaminergic neurons in serum-free suspension culture. Stem cells 22:1218-1238 (Pubitemid 39636400)
63. Schwab RS, Amador LV, Lettvin JY (1951) Apomorphine in Parkinson's disease. Trans Am Neurol Assoc 56:251-253
64. Schwab RS, England AC Jr, Poskanzer DC, Young RR (1969) Amantadine in the treatment of Parkinson's disease. JAMA 208:1168-1170
65. Simón-Sánchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, Krüger R, Federoff M, Klein C, Goate A, Perlmutter J, Bonin M, Nalls MA, Illig T, Gieger C, Houlden H, Steffens M, Okun MS, Racette BA, Cookson MR, Foote KD, Fernandez HH, Traynor BJ, Schreiber S, Arepalli S, Zonozi R, Gwinn K, van der Brug M, Lopez G, Chanock SJ, Schatzkin A, Park Y, Hollenbeck A, Gao J, Huang X, Wood NW, Lorenz D, Deuschl G, Chen H, Riess O, Hardy JA, Singleton AB, Gasser T (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 41:1308-1312
66. Takagi Y, Takahashi J, Saiki H, Morizane A, Hayashi T, Kishi Y, Fukuda H, Okamoto Y, Koyanagi M, Ideguchi M, Hayashi H, Imazato T, Kawasaki H, Suemori H, Omachi S, Iida H, Itoh N, Nakatsuji N, Sasai Y, Hashimoto N (2005) Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. J Clin Invest 115:102-109 (Pubitemid 40385510)
67. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861-872 (Pubitemid 350138099)
68. Trzaska KA, King CC, Li KY, Kuzhikandathil EV, Nowycky MC, Ye JH, Rameshwar P (2009) Brain-derived neurotrophic factor facilitates maturation of mesenchymal stem cell-derived dopamine progenitors to functional neurons. J Neurochem 110:1058-1069
69. Wenning GK, Odin P, Morrish P, Rehncrona S, Widner H, Brundin P, Rothwell JC, Brown R, Gustavii B, Hagell P, Jahanshahi M, Sawle G, Bjorklund A, Brooks DJ, Marsden CD, Quinn NP, Lindvall O (1997) Short-and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann Neurol 42:95-107 (Pubitemid 27304785)
70. Wernig M, Zhao J-P, Pruszak J, Hedlund E, Fu D, Soldner F, Broccoli V, Constantine-Paton M, Isacson O, Jaenisch R (2008) Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci USA 105:5856-5861 (Pubitemid 351758462)
71. Wijeyekoon R, Barker RA (2009) Cell replacement therapy for Parkinson's disease. Biochim Biophys Acta 1792:688-702
72. Yang D, Zhang ZJ, Oldenburg M, Ayala M, Zhang SC (2008) Human embryonic stem cell-derived dopaminergic neurons reverse functional deficit in parkinsonian rats. Stem cells 26:55-63